Thermo Fisher Scientific (TMO) — The Transparent Read
49/100Neutral$506.42 · mixed
This is a genuinely mixed chart, and the composite score of 48.9 (Neutral) reflects that honestly. Short-term momentum (above 50-day, positive MACD) is fighting a still-broken long-term trend (death cross, below 200-day). My lean is modestly constructive: the favorable macro base rate plus building momentum tips the scale slightly bullish, but only if buyers can clear $515.96. Until that resistance breaks, treat this as a range trade between roughly $457 support and $516 resistance — not a breakout to chase.
TMO key levels
Show Your Work — every point in TMO's score
The score starts at 50, then each signal below adds or subtracts points. No black box.
| Signal | Type | Points |
|---|---|---|
| Below 200-day MA Price is below its 200-day average — long-term trend is down. | technical | -8 |
| Above 50-day MA Trading above the 50-day average — medium-term momentum is positive. | technical | +5 |
| Death cross 50-day average is below the 200-day (death cross). | technical | -4 |
| RSI neutral RSI is 62 — neither overbought nor oversold. | technical | +1.24 |
| MACD positive MACD is above its signal line — momentum is building. | technical | +5 |
| Near resistance Pressing against resistance around $515.96. | technical | -4 |
| Macro regime base rate In 38 past periods like today (Rising inflation + Steady Fed), this stock was higher 90d later 68% of the time (median +4.4%). Historically favorable. | macro | +3.68 |
Macro regime base rate
Today's regime: Rising inflation + Steady Fed
In 38 past periods that looked like today, TMO was higher 90 days later 68% of the time (median move 4.4%). Confidence: high.
The read
TMO Caught Between Momentum and the 200-Day Wall
Bull case. Medium-term momentum is firmly in the bulls' favor: TMO trades above its rising 50-day MA at $473.80, the MACD histogram is positive at +4.33 with momentum building, and RSI at 62 leaves room before overbought territory. The macro backdrop is a tailwind too — in 38 analogous Rising-Inflation/Steady-Fed periods, TMO was higher 90 days later 68% of the time with a median gain of +4.4% (high confidence). A clean break above resistance at $515.96 would open the door back toward the 200-day.
Bear case. The long-term picture still leans negative. Price sits below the 200-day MA at $525.02, and the 50-day remains under the 200-day — a death cross that signals the broader trend hasn't healed. Right now TMO is pressing directly against resistance at $515.96, a logical spot for sellers to step in. A rejection here could send price back toward the 50-day or lower, with major support not until $457.64.
What would change my mind. A decisive close above $515.96 resistance — ideally followed by reclaiming the 200-day MA at $525.02 — would confirm the bullish thesis and flip the trend. Conversely, a failure at resistance and a close back below the 50-day MA at $473.80 would invalidate the constructive lean and put the $457.64 support level in play.
TMO — frequently asked
Is TMO a buy according to Tallyread?
Tallyread does not give buy or sell recommendations. It shows a transparent 49/100 read for Thermo Fisher Scientific (TMO), conditioned on today's macro regime, with every scoring input itemized so you can judge for yourself. This is not financial advice.
How is TMO's Tallyread score calculated?
The 49/100 score starts at 50, then adds and subtracts named technical and macro signals — each shown with its point value and a one-line reason in the "Show Your Work" table on this page. Nothing is hidden in a black box.
How does today's Fed-and-inflation regime affect TMO?
In 38 past periods whose macro regime matched today's (Rising inflation + Steady Fed), TMO was higher 90 days later 68% of the time, with a median move of 4.4%. Confidence: high.
Want a fresh read on TMO with the live chart and macro tape?
Run a live TMO read →Last analyzed 2026-06-30 · Data source: tiingo. See the public scorecard and methodology.
This is a historical and technical read for informational and educational purposes only — not financial advice, and not a recommendation to buy or sell TMO. Markets are uncertain; do your own research.